INSM (Insmed) Total Liabilities : $1,739.9 Mil (As of Dec. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Insmed Total Liabilities?

Insmed's Total Liabilities for the quarter that ended in Dec. 2024 was $1,739.9 Mil.

Insmed's quarterly Total Liabilities declined from Jun. 2024 ($1,771.30 Mil) to Sep. 2024 ($1,569.56 Mil) but then increased from Sep. 2024 ($1,569.56 Mil) to Dec. 2024 ($1,739.85 Mil).

Insmed's annual Total Liabilities increased from Dec. 2022 ($1,568.48 Mil) to Dec. 2023 ($1,661.76 Mil) and increased from Dec. 2023 ($1,661.76 Mil) to Dec. 2024 ($1,739.85 Mil).

Insmed Total Liabilities Historical Data

The historical data trend for Insmed's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insmed Total Liabilities Chart

Insmed Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

520.27

833.04

1,568.48

1,661.76

1,739.85

Insmed Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															1,661.76	1,623.90	1,771.30	1,569.56	1,739.85

Insmed Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Insmed's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	297.528	+	(1136.558	+	305.766
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	1,739.9

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	2025.231	-	285.379
	=	1,739.9

Insmed's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	297.528	+	(1136.558	+	305.766
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	1,739.9

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	2025.231	-	285.379
	=	1,739.9

Insmed Total Liabilities Related Terms

Thank you for viewing the detailed overview of Insmed's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Insmed Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Insmed Inc (NAS:INSM) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

0JAV:UK IM8N:Germany

Address

700 US Highway 202/206, Bridgewater, NJ, USA, 08807

Website

https://www.insmed.com

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Executives

William Lewis	officer: President & CEO	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Sara Bonstein	officer: Chief Financial Officer	305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Flammer Martina M.d.	officer: Chief Medical Officer	700 US HIGHWAY 202/206, BRIDGEWATER NJ 08807
Roger Adsett	officer: Chief Commercial Officer	10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
John Drayton Wise	officer: Chief Commercial Officer	700 US HIGHWAY 202/206, BRIDGEWATER NJ 08807
Michael Alexander Smith	officer: General Counsel, Senior VP	700 US HIGHWAY 202/206, BRIDGEWATER NJ 08807
Schaeffer Orlov S Nicole	officer: Chief People Strategy Officer	INSMED INCORPORATED, 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Melvin Md Sharoky	director	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Leo Lee	director	10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
David R Brennan	director	C/O INSMED INCORPORATED, 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Steinar J Engelsen	director	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
John Soriano	officer: Chief Compliance Officer	10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Christine A Pellizzari	officer: General Counsel & Secretary	10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Alfred Altomari	director	C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
Elizabeth M Anderson	director	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807